Trial Profile
A Retrospective Study Assessing the Safety and Efficacy of Mogamulizumab (MOG) in Patients with Adult T cell Leukemia/Lymphoma (ATLL) before Allo-Hematopoietic Stem Cell Transplantation (allo-HSCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2018 New trial record